26 Papers
72 Citations
Guo Chen is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 15, co-authored 20 publications. Previous affiliations of Guo Chen include Mayo Clinic.
Chat about Author
Papers
A landscape of driver mutations in melanoma
Eran Hodis,Ian R. Watson,Ian R. Watson,Gregory V. Kryukov,Gregory V. Kryukov,Gregory V. Kryukov,Stefan T. Arold,Marcin Imielinski,Jean Philippe Theurillat,Elizabeth Nickerson,Daniel Auclair,Liren Li,Liren Li,Chelsea S. Place,Daniel DiCara,Alex H. Ramos,Alex H. Ramos,Michael S. Lawrence,Kristian Cibulskis,Andrey Sivachenko,Douglas Voet,Gordon Saksena,Nicolas Stransky,Robert C. Onofrio,Wendy Winckler,Kristin G. Ardlie,Nikhil Wagle,Nikhil Wagle,Jennifer A. Wargo,Kelly Chong,Donald L. Morton,Katherine Stemke-Hale,Guo Chen,Michael S. Noble,Matthew Meyerson,John E. Ladbury,Michael A. Davies,Jeffrey E. Gershenwald,Stephan N. Wagner,Dave S.B. Hoon,Dirk Schadendorf,Eric S. Lander,Eric S. Lander,Stacey Gabriel,Gad Getz,Levi A. Garraway,Lynda Chin +46 more
TL;DR: The spectrum of driver mutations provided unequivocal genomic evidence for a direct mutagenic role of UV light in melanoma pathogenesis, providing oncogenic insights in BRAF- and NRAS-driven melanoma as well as those without known NRAS/BRAF mutations.
2.6K
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng,Jie Qing Chen,Chengwen Liu,Shruti Malu,Caitlin Creasy,Michael T. Tetzlaff,Chunyu Xu,Jodi A. McKenzie,Chunlei Zhang,Xiaoxuan Liang,Leila Williams,Wanleng Deng,Guo Chen,Rina M. Mbofung,Alexander J. Lazar,Carlos A. Torres-Cabala,Zachary A. Cooper,Pei-Ling Chen,Trang N. Tieu,Stefani Spranger,Xiaoxing Yu,Chantale Bernatchez,Marie-Andree Forget,Cara Haymaker,Rodabe N. Amaria,Jennifer L. McQuade,Isabella C. Glitza,Tina Cascone,Haiyan S. Li,Lawrence N. Kwong,Timothy P. Heffernan,Jianhua Hu,Roland L. Bassett,Marcus Bosenberg,Scott E. Woodman,Willem W. Overwijk,Gregory Lizée,Jason Roszik,Thomas F. Gajewski,Jennifer A. Wargo,Jeffrey E. Gershenwald,Laszlo Radvanyi,Michael A. Davies,Patrick Hwu +43 more
TL;DR: It is demonstrated that loss of PTEN in tumor cells in preclinical models of melanoma inhibits T cell-mediated tumor killing and decreases T-cell trafficking into tumors, and support the rationale to explore combinations of immunotherapies and PI3K-AKT pathway inhibitors.
Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma
Y.N. Vashisht Gopal,Helen Rizos,Guo Chen,Wanleng Deng,Dennie T. Frederick,Zachary A. Cooper,Richard A. Scolyer,Gulietta M. Pupo,Kakajan Komurov,Vasudha Sehgal,Jiexin Zhang,Lalit R. Patel,Cristiano Gonçalves Pereira,Bradley M. Broom,Gordon B. Mills,Prahlad T. Ram,Paul D. Smith,Jennifer A. Wargo,Georgina V. Long,Michael A. Davies +19 more
TL;DR: The findings highlight the significance of OxPhos in melanoma and suggest that combined targeting of the MAPK and mTORC pathways may offer an effective therapeutic strategy to treat melanomas with this metabolic phenotype.
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations
Amanda D. Bucheit,Guo Chen,Alan E. Siroy,Michael T. Tetzlaff,Russell Broaddus,Denái R. Milton,Patricia S. Fox,Roland L. Bassett,Patrick Hwu,Jeffrey E. Gershenwald,Alexander J. Lazar,Michael A. Davies +11 more
TL;DR: Analysis of PTEN in mutationally defined subsets showed thatPTEN loss was significantly associated with OS and time to MBM in patients with BRAFV600 mutations, adding to evidence supporting a significant role for PTEN loss and the PI3K–AKT pathway in melanoma.
173
AKT1 Activation Promotes Development of Melanoma Metastases
Joseph H. Cho,James P. Robinson,Rowan A. Arave,William J. Burnett,David A. Kircher,Guo Chen,Michael A. Davies,Allie H. Grossmann,Matthew W. VanBrocklin,Martin McMahon,Sheri L. Holmen,Sheri L. Holmen +11 more
TL;DR: It is demonstrated that AKT1 activation is sufficient to elicit lung and brain metastases in this context and revealed that activation ofAKT1 is distinct from PTEN silencing in metastatic melanoma progression.
138